{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:16:50Z","timestamp":1791159410215,"version":"4.1.0"},"reference-count":265,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>It is evident that the emergence of infectious diseases, which have the potential for spillover from animal reservoirs, pose an ongoing threat to global health. Zoonotic transmission events have increased in frequency in recent decades due to changes in human behavior, including increased international travel, the wildlife trade, deforestation, and the intensification of farming practices to meet demand for meat consumption. Influenza A viruses (IAV) possess a number of features which make them a pandemic threat and a major concern for human health. Their segmented genome and error-prone process of replication can lead to the emergence of novel reassortant viruses, for which the human population are immunologically na\u00efve. In addition, the ability for IAVs to infect aquatic birds and domestic animals, as well as humans, increases the likelihood for reassortment and the subsequent emergence of novel viruses. Sporadic spillover events in the past few decades have resulted in human infections with highly pathogenic avian influenza (HPAI) viruses, with high mortality. The application of conventional vaccine platforms used for the prevention of seasonal influenza viruses, such as inactivated influenza vaccines (IIVs) or live-attenuated influenza vaccines (LAIVs), in the development of vaccines for HPAI viruses is fraught with challenges. These issues are associated with manufacturing under enhanced biosafety containment, and difficulties in propagating HPAI viruses in embryonated eggs, due to their propensity for lethality in eggs. Overcoming manufacturing hurdles through the use of safer backbones, such as low pathogenicity avian influenza viruses (LPAI), can also be a challenge if incompatible with master strain viruses. Non-replicating adenoviral (Ad) vectors offer a number of advantages for the development of vaccines against HPAI viruses. Their genome is stable and permits the insertion of HPAI virus antigens (Ag), which are expressed<jats:italic>in vivo<\/jats:italic>following vaccination. Therefore, their manufacture does not require enhanced biosafety facilities or procedures and is egg-independent. Importantly, Ad vaccines have an exemplary safety and immunogenicity profile in numerous human clinical trials, and can be thermostabilized for stockpiling and pandemic preparedness. This review will discuss the status of Ad-based vaccines designed to protect against avian influenza viruses with pandemic potential.<\/jats:p>","DOI":"10.3389\/fimmu.2020.607333","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T04:46:47Z","timestamp":1611895607000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses"],"prefix":"10.3389","volume":"11","author":[{"given":"Lucas J.","family":"Kerstetter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly M.","family":"Bliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Coughlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc3189","article-title":"Ecology and economics for pandemic prevention","volume":"369","author":"Dobson","year":"2020","journal-title":"Sci (New York NY"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2054","article-title":"Scientific barriers to developing vaccines against avian influenza viruses","volume":"7","author":"Subbarao","year":"2007","journal-title":"Nat Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","article-title":"Influenza","volume":"4","author":"Krammer","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0143-6","article-title":"The human antibody response to influenza A virus infection and vaccination","volume":"19","author":"Krammer","year":"2019","journal-title":"Nat Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.10.2000153","article-title":"Interim 2019\/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020","volume":"25","author":"Rose","year":"2020","journal-title":"Euro Surveill"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2019.24.1900121","article-title":"Interim 2018\/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019","volume":"24","author":"Kissling","year":"2019","journal-title":"Euro Surveill"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-101416-041726","article-title":"Constraints, Drivers, and Implications of Influenza A Virus Reassortment","volume":"4","author":"Lowen","year":"2017","journal-title":"Annu Rev Virol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1099\/jgv.0.000989","article-title":"Implications of segment mismatch for influenza A virus evolution","volume":"99","author":"White","year":"2018","journal-title":"J Gen Virol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1818494116","article-title":"H5N8 and H7N9 packaging signals constrain HA reassortment with a seasonal H3N2 influenza A virus","volume":"116","author":"White","year":"2019","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41579-018-0115-z","article-title":"Host and viral determinants of influenza A virus species specificity","volume":"17","author":"Long","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00217-19","article-title":"ANP32 Proteins Are Essential for Influenza Virus Replication in Human Cells","volume":"93","author":"Staller","year":"2019","journal-title":"J Virol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2007.070248","article-title":"Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals","volume":"171","author":"van Riel","year":"2007","journal-title":"Am J Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/440435a","article-title":"Avian flu: influenza virus receptors in the human airway","volume":"440","author":"Shinya","year":"2006","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/v12060589","article-title":"Avian Influenza A Virus Infects Swine Airway Epithelial Cells without Prior Adaptation","volume":"12","author":"Shin","year":"2020","journal-title":"Viruses"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.74.24.11825-11831.2000","article-title":"Sialic acid species as a determinant of the host range of influenza A viruses","volume":"74","author":"Suzuki","year":"2000","journal-title":"J Virol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.72.9.7367-7373.1998","article-title":"Molecular basis for the generation in pigs of influenza A viruses with pandemic potential","volume":"72","author":"Ito","year":"1998","journal-title":"J Virol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2018.00347","article-title":"Adaptation of Human Influenza Viruses to Swine","volume":"5","author":"Rajao","year":"2018","journal-title":"Front Vet Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00132-20","article-title":"Swine ANP32A Supports Avian Influenza Virus Polymerase","volume":"94","author":"Peacock","year":"2020","journal-title":"J Virol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01783-09","article-title":"Molecular determinants of adaptation of highly pathogenic avian influenza H7N7 viruses to efficient replication in the human host","volume":"84","author":"de Wit","year":"2010","journal-title":"J Virol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01399-13","article-title":"The effect of the PB2 mutation 627K on highly pathogenic H5N1 avian influenza virus is dependent on the virus lineage","volume":"87","author":"Long","year":"2013","journal-title":"J Virol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nature10831","article-title":"Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA\/H1N1 virus in ferrets","volume":"486","author":"Imai","year":"2012","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.1213362","article-title":"Airborne transmission of influenza A\/H5N1 virus between ferrets","volume":"336","author":"Herfst","year":"2012","journal-title":"Sci (New York NY"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5349.393","article-title":"Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness","volume":"279","author":"Subbarao","year":"1998","journal-title":"Sci (New York NY"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11212-0","article-title":"Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus","volume":"351","author":"Claas","year":"1998","journal-title":"Lancet (London England)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15589-X","article-title":"Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands","volume":"363","author":"Koopmans","year":"2004","journal-title":"Lancet (London England)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308352100","article-title":"Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome","volume":"101","author":"Fouchier","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304459","article-title":"Human infection with a novel avian-origin influenza A (H7N9) virus","volume":"368","author":"Gao","year":"2013","journal-title":"New Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41426-018-0070-9","article-title":"Wild ducks excrete highly pathogenic avian influenza virus H5N8 (2014-2015) without clinical or pathological evidence of disease","volume":"7","author":"van den Brand","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf8852","article-title":"Role for migratory wild birds in the global spread of avian influenza H5N8","volume":"354","author":"Global Consortium for","year":"2016","journal-title":"Sci (New York NY"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007857","article-title":"Agricultural and geographic factors shaped the North American 2015 highly pathogenic avian influenza H5N2 outbreak","volume":"16","author":"Hicks","year":"2020","journal-title":"PloS Pathog"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.59212","article-title":"Poultry farmer response to disease outbreaks in smallholder farming systems in southern Vietnam","volume":"9","author":"Delabouglise","year":"2020","journal-title":"Elife"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/srep46441","article-title":"Assessment of China\u2019s H5N1 routine vaccination strategy","volume":"7","author":"Sun","year":"2017","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3201\/eid1209.060430","article-title":"Control of avian influenza in poultry","volume":"12","author":"Capua","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84428","article-title":"Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection","volume":"126","author":"DiLillo","year":"2016","journal-title":"J Clin Invest"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc\u03b3R interactions for protection against influenza virus in vivo","volume":"20","author":"DiLillo","year":"2014","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41467-017-00928-3","article-title":"Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice","volume":"8","author":"He","year":"2017","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4161\/hv.22908","article-title":"Correlates of protection to influenza virus, where do we go from here","volume":"9","author":"Cox","year":"2013","journal-title":"Hum Vaccines Immunother"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-327-5_19","article-title":"Evaluation of antibody-dependent cell cytotoxicity using lactate dehydrogenase (LDH) measurement","volume":"988","author":"Broussas","year":"2013","journal-title":"Methods Mol Biol (Clifton NJ"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1991.tb01830.x","article-title":"Release of esterase from murine lymphokine-activated killer cells in antibody-dependent cellular cytotoxic reaction","volume":"82","author":"Kato","year":"1991","journal-title":"Jpn J Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jim.2005.09.018","article-title":"A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity","volume":"308","author":"Gomez-Roman","year":"2006","journal-title":"J Immunol Methods"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.52.5.483","article-title":"Direct evidence for release of pore-forming protein during NK cellular lysis","volume":"52","author":"Ortaldo","year":"1992","journal-title":"J Leukoc Biol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00399","article-title":"HA Antibody-Mediated FcgammaRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids","volume":"7","author":"Cox","year":"2016","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ymeth.2015.04.037","article-title":"Measuring the neutralization potency of influenza A virus hemagglutinin stalk\/stem-binding antibodies in polyclonal preparations by microneutralization assay","volume":"90","author":"He","year":"2015","journal-title":"Methods (San Diego Calif)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1609316113","article-title":"Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus","volume":"113","author":"He","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1613225113","article-title":"Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact","volume":"113","author":"Leon","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.01.008","article-title":"Activity of human serum antibodies in an influenza virus hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay","volume":"38","author":"Chromikova","year":"2020","journal-title":"Vaccine"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00332","article-title":"Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses","volume":"10","author":"Tay","year":"2019","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1084\/jem.175.4.1143","article-title":"Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge","volume":"175","author":"Bender","year":"1992","journal-title":"J Exp Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1929","article-title":"Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10","volume":"15","author":"Sun","year":"2009","journal-title":"Nat Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"6833","DOI":"10.1038\/ncomms7833","article-title":"Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8(+) T cells","volume":"6","author":"Wang","year":"2015","journal-title":"Nat Commun"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3350","article-title":"Cellular immune correlates of protection against symptomatic pandemic influenza","volume":"19","author":"Sridhar","year":"2013","journal-title":"Nat Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2612","article-title":"Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans","volume":"18","author":"Wilkinson","year":"2012","journal-title":"Nat Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198307073090103","article-title":"Cytotoxic T-cell immunity to influenza","volume":"309","author":"McMichael","year":"1983","journal-title":"New Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/infdis\/jis684","article-title":"CD4+ T-cell expansion predicts neutralizing antibody responses to monovalent, inactivated 2009 pandemic influenza A(H1N1) virus subtype H1N1 vaccine","volume":"207","author":"Nayak","year":"2013","journal-title":"J Infect Dis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201411-1988OC","article-title":"Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study","volume":"191","author":"Hayward","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12350","article-title":"Adenoviral vectors as novel vaccines for influenza","volume":"67","author":"Coughlan","year":"2015","journal-title":"J Pharm Pharmacol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002572","article-title":"Influenza A virus infection of human primary dendritic cells impairs their ability to cross-present antigen to CD8 T cells","volume":"8","author":"Smed-Sorensen","year":"2012","journal-title":"PloS Pathog"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1038\/s41467-019-10661-8","article-title":"Quantification of epitope abundance reveals the effect of direct and cross-presentation on influenza CTL responses","volume":"10","author":"Wu","year":"2019","journal-title":"Nat Commun"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.04.009","article-title":"Research Techniques Made Simple: Monitoring of T-Cell Subsets using the ELISPOT Assay","volume":"136","author":"Mobs","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/cells3041116","article-title":"Triple Cytokine FluoroSpot Analysis of Human Antigen-Specific IFN-gamma, IL-17A and IL-22 Responses","volume":"3","author":"Dillenbeck","year":"2014","journal-title":"Cells"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/s1046-2023(03)00124-5","article-title":"Quantification and characterization of specific T-cells by antigen-specific cytokine production using ELISPOT assay or intracellular cytokine staining","volume":"31","author":"Letsch","year":"2003","journal-title":"Methods"},{"key":"B62","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41598-018-37167-5","article-title":"Differences in the influenza-specific CD4 T cell immunodominance hierarchy and functional potential between children and young adults","volume":"9","author":"Shannon","year":"2019","journal-title":"Sci Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1602488113","article-title":"Detection, phenotyping, and quantification of antigen-specific T cells using a peptide-MHC dodecamer","volume":"113","author":"Huang","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1172\/jci8476","article-title":"MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen","volume":"104","author":"Novak","year":"1999","journal-title":"J Clin Invest"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02692","article-title":"Defining Memory CD8 T Cell","volume":"9","author":"Martin","year":"2018","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.78.13.7284-7287.2004","article-title":"Ex vivo phenotype and frequency of influenza virus-specific CD4 memory T cells","volume":"78","author":"Lucas","year":"2004","journal-title":"J Virol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.02.011","article-title":"Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults","volume":"29","author":"Coughlan","year":"2018","journal-title":"EBioMedicine"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses","volume":"215","author":"Pardi","year":"2018","journal-title":"J Exp Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1038\/s41467-018-05482-0","article-title":"Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies","volume":"9","author":"Pardi","year":"2018","journal-title":"Nat Commun"},{"key":"B71","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3390\/vaccines3020293","article-title":"Measuring Cellular Immunity to Influenza: Methods of Detection, Applications and Challenges","volume":"3","author":"Coughlan","year":"2015","journal-title":"Vaccines"},{"key":"B72","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.chom.2018.06.016","article-title":"Overcoming Barriers in the Path to a Universal Influenza Virus Vaccine","volume":"24","author":"Coughlan","year":"2018","journal-title":"Cell Host Microbe"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2011.70","article-title":"Return of inactivated whole-virus vaccine for superior efficacy","volume":"90","author":"Furuya","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00932","article-title":"Imprinting and Editing of the Human CD4 T Cell Response to Influenza Virus","volume":"10","author":"Nelson","year":"2019","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"New Engl J Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68656-X","article-title":"Safety and immunogenicity of an inactivated split-virion influenza A\/Vietnam\/1194\/2004 (H5N1) vaccine: phase I randomised trial","volume":"367","author":"Bresson","year":"2006","journal-title":"Lancet (London England)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/s0264-410x(02)00632-1","article-title":"Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A\/Duck\/Singapore\/97 vaccine in a primed human population","volume":"21","author":"Stephenson","year":"2003","journal-title":"Vaccine"},{"key":"B78","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.virusres.2013.05.006","article-title":"H5N1 vaccines in humans","volume":"178","author":"Baz","year":"2013","journal-title":"Virus Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1473-3099(10)70296-6","article-title":"Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial","volume":"11","author":"Nicholson","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix165","article-title":"Boosting of Cross-Reactive and Protection-Associated T Cells in Children After Live Attenuated Influenza Vaccination","volume":"215","author":"Mohn","year":"2017","journal-title":"J Infect Dis"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines3020373","article-title":"Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines","volume":"3","author":"Sridhar","year":"2015","journal-title":"Vaccines"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00287","article-title":"Boosted Influenza-Specific T Cell Responses after H5N1 Pandemic Live Attenuated Influenza Virus Vaccination","volume":"6","author":"Peng","year":"2015","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.chom.2015.02.012","article-title":"Influenza vaccines: challenges and solutions","volume":"17","author":"Houser","year":"2015","journal-title":"Cell Host Microbe"},{"key":"B84","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/ni.2761","article-title":"Universal influenza virus vaccines: need for clinical trials","volume":"15","author":"Krammer","year":"2014","journal-title":"Nat Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp048290","article-title":"Weathering the influenza vaccine crisis","volume":"351","author":"Treanor","year":"2004","journal-title":"New Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/s0264-410x(03)00071-9","article-title":"The annual production cycle for influenza vaccine","volume":"21","author":"Gerdil","year":"2003","journal-title":"Vaccine"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy103","article-title":"A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases","volume":"218","author":"Erbelding","year":"2018","journal-title":"J Infect Dis"},{"key":"B88","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.immuni.2017.09.007","article-title":"The Pathway to a Universal Influenza Vaccine","volume":"47","author":"Paules","year":"2017","journal-title":"Immunity"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1714916","article-title":"Chasing Seasonal Influenza - The Need for a Universal Influenza Vaccine","author":"Paules","year":"2017","journal-title":"New Engl J Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024626","article-title":"Cross-protective peptide vaccine against influenza A viruses developed in HLA-A*2402 human immunity model","volume":"6","author":"Ichihashi","year":"2011","journal-title":"PloS One"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101399","article-title":"Incorporation of a Novel CD4+ Helper Epitope Identified from Aquifex aeolicus Enhances Humoral Responses Induced by DNA and Protein Vaccinations","volume":"23","author":"Xu","year":"2020","journal-title":"iScience"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.02.038","article-title":"Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine","volume":"32","author":"Yan","year":"2014","journal-title":"Vaccine"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.04.018","article-title":"A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice","volume":"28","author":"Freyn","year":"2020","journal-title":"Mol Ther"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3927","article-title":"Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection","volume":"21","author":"Yassine","year":"2015","journal-title":"Nat Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201902802","article-title":"In Vivo Assembly of Nanoparticles Achieved through Synergy of Structure-Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity","volume":"7","author":"Xu","year":"2020","journal-title":"Adv Sci (Weinh)"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02052-06","article-title":"Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus","volume":"81","author":"Quan","year":"2007","journal-title":"J Virol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1586\/erv.12.70","article-title":"Virus-like particles as universal influenza vaccines","volume":"11","author":"Kang","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00909","article-title":"Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines","volume":"11","author":"Coughlan","year":"2020","journal-title":"Front Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-008748","article-title":"Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults","volume":"5","author":"Green","year":"2015","journal-title":"BMJ Open"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70345-6","article-title":"Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study","volume":"13","author":"Gurwith","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.11.003","article-title":"Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants","volume":"25","author":"Bliss","year":"2017","journal-title":"Mol Ther"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01551","article-title":"Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial","volume":"8","author":"Mensah","year":"2017","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.83","article-title":"Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants","volume":"24","author":"Afolabi","year":"2016","journal-title":"Mol Ther"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411627","article-title":"A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"New Engl J Med"},{"key":"B105","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet (London England)"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis670","article-title":"First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)","volume":"207","author":"Baden","year":"2013","journal-title":"J Infect Dis"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis671","article-title":"Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001)","volume":"207","author":"Barouch","year":"2013","journal-title":"J Infect Dis"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.02.004","article-title":"The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells\/mm(3)","volume":"33","author":"Churchyard","year":"2015","journal-title":"Vaccine"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet (London England)"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet (London England)"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet (London England)"},{"key":"B114","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41541-020-00221-3","article-title":"Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19","volume":"5","author":"Graham","year":"2020","journal-title":"NPJ Vaccines"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1070-6","article-title":"Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters","author":"Tostanoski","year":"2020","journal-title":"Nat Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202861","article-title":"Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization","volume":"190","author":"Quinn","year":"2013","journal-title":"J Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01597-10","article-title":"Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors","volume":"85","author":"Rhee","year":"2011","journal-title":"J Virol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02192-06","article-title":"Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways","volume":"81","author":"Zhu","year":"2007","journal-title":"J Virol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/nature06664","article-title":"The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response","volume":"452","author":"Muruve","year":"2008","journal-title":"Nature"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1159\/000207194","article-title":"TRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses","volume":"1","author":"Appledorn","year":"2009","journal-title":"J Innate Immun"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.3.2134","article-title":"Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo","volume":"181","author":"Appledorn","year":"2008","journal-title":"J Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-062117","article-title":"Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines","volume":"110","author":"Tatsis","year":"2007","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00720-16","article-title":"Replicating Single-Cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses","volume":"91","author":"Crosby","year":"2017","journal-title":"J Virol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"e73313","DOI":"10.1371\/journal.pone.0073313","article-title":"Low seroprevalent species D adenovirus vectors as influenza vaccines","volume":"8","author":"Weaver","year":"2013","journal-title":"PloS One"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140702","article-title":"Centralized Consensus Hemagglutinin Genes Induce Protective Immunity against H1, H3 and H5 Influenza Viruses","volume":"10","author":"Webby","year":"2015","journal-title":"PloS One"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031177","article-title":"Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin","volume":"7","author":"Alexander","year":"2012","journal-title":"PloS One"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.07.035","article-title":"Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein","volume":"25","author":"Roy","year":"2007","journal-title":"Vaccine"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.01630","article-title":"Influenza Vaccine With Consensus Internal Antigens as Immunogens Provides Cross-Group Protection Against Influenza A Viruses","volume":"10","author":"Xie","year":"2019","journal-title":"Front Microbiol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600939","article-title":"Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge","author":"Tully","year":"2017","journal-title":"J Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02005","article-title":"Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge","volume":"10","author":"McMahon","year":"2019","journal-title":"Front Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.07.095","article-title":"Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice","volume":"37","author":"Asthagiri Arunkumar","year":"2019","journal-title":"Vaccine"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015301","article-title":"A porcine adenovirus with low human seroprevalence is a promising alternative vaccine vector to human adenovirus 5 in an H5N1 virus disease model","volume":"5","author":"Patel","year":"2010","journal-title":"PloS One"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.07.007","article-title":"A Bovine Adenoviral Vector-Based H5N1 Influenza -Vaccine Provides Enhanced Immunogenicity and Protection at a Significantly Low Dose","volume":"10","author":"Sayedahmed","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B134","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/sj.mt.6300024","article-title":"Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector","volume":"15","author":"Hensley","year":"2007","journal-title":"Mol Ther"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1172\/JCI78280","article-title":"Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling","volume":"125","author":"Quinn","year":"2015","journal-title":"J Clin Invest"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.129035","article-title":"Hemagglutinin head-specific responses dominate over stem-specific responses following prime boost with mismatched vaccines","volume":"4","author":"Jegaskanda","year":"2019","journal-title":"JCI Insight"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02481-15","article-title":"Hemagglutinin stalk immunity reduces influenza virus replication and transmission in ferrets","volume":"90","author":"Nachbagauer","year":"2015","journal-title":"J Virol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/npjvaccines.2016.15","article-title":"A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice","volume":"1","author":"Nachbagauer","year":"2016","journal-title":"NPJ Vaccines"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00641-13","article-title":"Chimeric Hemagglutinin Influenza Virus Vaccine Constructs Elicit Broadly Protective Stalk-Specific Antibodies","volume":"87","author":"Krammer","year":"2013","journal-title":"J Virol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03183-13","article-title":"H3 Stalk-Based Chimeric Hemagglutinin Influenza Virus Constructs Protect Mice from H7N9 Challenge","volume":"88","author":"Krammer","year":"2014","journal-title":"J Virol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00137-12","article-title":"Influenza Viruses Expressing Chimeric Hemagglutinins: Globular Head and Stalk Domains Derived from Different Subtypes","volume":"86","author":"Hai","year":"2012","journal-title":"J Virol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00333-19","article-title":"Development of Influenza B Universal Vaccine Candidates Using the \u201cMosaic\u201d Hemagglutinin Approach","volume":"93","author":"Sun","year":"2019","journal-title":"J Virol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41541-019-0126-4","article-title":"A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains","volume":"4","author":"Broecker","year":"2019","journal-title":"NPJ Vaccines"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.05.038","article-title":"Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses","volume":"33","author":"Wohlbold","year":"2015","journal-title":"Vaccine"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/srep22666","article-title":"Stalking influenza by vaccination with pre-fusion headless HA mini-stem","volume":"6","author":"Valkenburg","year":"2016","journal-title":"Sci Rep"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.00018-10","article-title":"Influenza virus vaccine based on the conserved hemagglutinin stalk domain","volume":"1","author":"Steel","year":"2010","journal-title":"mBio"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac7263","article-title":"A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen","volume":"349","author":"Impagliazzo","year":"2015","journal-title":"Sci (New York NY)"},{"key":"B148","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41541-017-0036-2","article-title":"Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines","volume":"2","author":"Sutton","year":"2017","journal-title":"NPJ Vaccines"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039075","article-title":"Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles","volume":"7","author":"Lin","year":"2012","journal-title":"PloS One"},{"key":"B150","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1128\/JVI.02608-13","article-title":"Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain","volume":"88","author":"Eggink","year":"2014","journal-title":"J Virol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1816300116","article-title":"Outflanking immunodominance to target subdominant broadly neutralizing epitopes","volume":"116","author":"Angeletti","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1172\/JCI123366","article-title":"Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting influenza HA stem","volume":"129","author":"Tan","year":"2019","journal-title":"J Clin Invest"},{"key":"B153","doi-asserted-by":"publisher","first-page":"316ra192","DOI":"10.1126\/scitranslmed.aad0522","article-title":"Immune history profoundly affects broadly protective B cell responses to influenza","volume":"7","author":"Andrews","year":"2015","journal-title":"Sci Trans Med"},{"key":"B154","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.immuni.2020.10.005","article-title":"Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses","volume":"162","author":"Guthmiller","year":"2020","journal-title":"Immunity"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.06.026","article-title":"Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy","volume":"162","author":"Wang","year":"2015","journal-title":"Cell"},{"key":"B156","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41541-017-0026-4","article-title":"A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies","volume":"2","author":"Nachbagauer","year":"2017","journal-title":"NPJ Vaccines"},{"key":"B157","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/S1473-3099(19)30393-7","article-title":"Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial","volume":"20","author":"Bernstein","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01526-18","article-title":"Hemagglutinin Stalk-Reactive Antibodies Interfere with Influenza Virus Neuraminidase Activity by Steric Hindrance","volume":"93","author":"Chen","year":"2019","journal-title":"J Virol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.12.7381","article-title":"Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections","volume":"166","author":"Huber","year":"2001","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006366","article-title":"Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease","volume":"5","author":"Khurana","year":"2013","journal-title":"Sci Trans Med"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.08.072","article-title":"The type of adjuvant in whole inactivated influenza a virus vaccines impacts vaccine-associated enhanced respiratory disease","volume":"36","author":"Souza","year":"2018","journal-title":"Vaccine"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00315-12","article-title":"Intranasal vaccination with replication-defective adenovirus type 5 encoding influenza virus hemagglutinin elicits protective immunity to homologous challenge and partial protection to heterologous challenge in pigs","volume":"19","author":"Braucher","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1821317116","article-title":"Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics","volume":"116","author":"Winarski","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1906613117","article-title":"Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans","volume":"117","author":"Ellebedy","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B165","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41541-019-0147-z","article-title":"Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts","volume":"4","author":"Nachbagauer","year":"2019","journal-title":"NPJ Vaccines"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1200039109","article-title":"Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses","volume":"109","author":"Pica","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0463-x","article-title":"Novel correlates of protection against pandemic H1N1 influenza A virus infection","volume":"25","author":"Ng","year":"2019","journal-title":"Nat Med"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-10-321","article-title":"Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase","volume":"10","author":"Cohen","year":"2013","journal-title":"Virol J"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00967-13","article-title":"The short stalk length of highly pathogenic avian influenza H5N1 virus neuraminidase limits transmission of pandemic H1N1 virus in ferrets","volume":"87","author":"Blumenkrantz","year":"2013","journal-title":"J Virol"},{"key":"B170","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/0042-6822(74)90276-1","article-title":"Characterization of temperature sensitive influenza virus mutants defective in neuraminidase","volume":"61","author":"Palese","year":"1974","journal-title":"Virology"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3390\/v6062465","article-title":"In the shadow of hemagglutinin: A growing interest in influenza viral neuraminidase and its role as a vaccine antigen","volume":"6","author":"Wohlbold","year":"2014","journal-title":"Viruses"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02332-17","article-title":"NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines","volume":"9","author":"Krammer","year":"2018","journal-title":"mBio"},{"key":"B173","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.virol.2012.06.003","article-title":"Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice","volume":"432","author":"Easterbrook","year":"2012","journal-title":"Virology"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.2.8.778-786.1968","article-title":"Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice","volume":"2","author":"Schulman","year":"1968","journal-title":"J Virol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02556-14","article-title":"Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice","volume":"6","author":"Wohlbold","year":"2015","journal-title":"mBio"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.24.1.157-160.1986","article-title":"Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus","volume":"24","author":"Clements","year":"1986","journal-title":"J Clin Microbiol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/129.4.411","article-title":"Induction of partial immunity to influenza by a neuraminidase-specific vaccine","volume":"129","author":"Couch","year":"1974","journal-title":"J Infect Dis"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197206222862502","article-title":"Association of serum anti-neuraminidase antibody with resistance to influenza in man","volume":"286","author":"Murphy","year":"1972","journal-title":"New Engl J Med"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.19.6869","article-title":"Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins","volume":"84","author":"Johansson","year":"1987","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.67.10.5721-5723.1993","article-title":"Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition","volume":"67","author":"Johansson","year":"1993","journal-title":"J Virol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.7.5493-5501.1998","article-title":"Influenza virus nucleoprotein interacts with influenza virus polymerase proteins","volume":"72","author":"Biswas","year":"1998","journal-title":"J Virol"},{"key":"B182","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/ncomms2589","article-title":"The role and assembly mechanism of nucleoprotein in influenza A virus ribonucleoprotein complexes","volume":"4","author":"Turrell","year":"2013","journal-title":"Nat Commun"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.71.4.2947-2958.1997","article-title":"Association of influenza virus NP and M1 proteins with cellular cytoskeletal elements in influenza virus-infected cells","volume":"71","author":"Avalos","year":"1997","journal-title":"J Virol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001190","article-title":"Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets","volume":"2","author":"Heiny","year":"2007","journal-title":"PloS One"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.04.047","article-title":"Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein","volume":"23","author":"Epstein","year":"2005","journal-title":"Vaccine"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32460","article-title":"Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals","volume":"118","author":"Lee","year":"2008","journal-title":"J Clin Invest"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.04.029","article-title":"What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins","volume":"8","author":"Vanderven","year":"2016","journal-title":"EBioMedicine"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw629","article-title":"Induction of H7N9-Cross-Reactive Antibody-Dependent Cellular Cytotoxicity Antibodies by Human Seasonal Influenza A Viruses that are Directed Toward the Nucleoprotein","volume":"215","author":"Jegaskanda","year":"2017","journal-title":"J Infect Dis"},{"key":"B189","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.126.5.1814","article-title":"Expression of influenza A virus internal antigens on the surface of infected P815 cells","volume":"126","author":"Yewdell","year":"1981","journal-title":"J Immunol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003057","article-title":"Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus","volume":"186","author":"LaMere","year":"2011","journal-title":"J Immunol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.6.4168","article-title":"A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus","volume":"181","author":"Carragher","year":"2008","journal-title":"J Immunol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00091-15","article-title":"Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice","volume":"22","author":"Wang","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-380121","article-title":"Properties of mouse and human IgG receptors and their contribution to disease models","volume":"119","author":"Bruhns","year":"2012","journal-title":"Blood"},{"key":"B194","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/imr.12350","article-title":"Mouse and human FcR effector functions","volume":"268","author":"Bruhns","year":"2015","journal-title":"Immunol Rev"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.82809-0","article-title":"Identification of the domains of the influenza A virus M1 matrix protein required for NP binding, oligomerization and incorporation into virions","volume":"88","author":"Noton","year":"2007","journal-title":"J Gen Virol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.74.10.4634-4644.2000","article-title":"Influenza virus assembly and lipid raft microdomains: a role for the cytoplasmic tails of the spike glycoproteins","volume":"74","author":"Zhang","year":"2000","journal-title":"J Virol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.74.18.8709-8719.2000","article-title":"Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein","volume":"74","author":"Ali","year":"2000","journal-title":"J Virol"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00161-19","article-title":"Deep Mutational Scan of the Highly Conserved Influenza A Virus M1 Matrix Protein Reveals Substantial Intrinsic Mutational Tolerance","volume":"93","author":"Hom","year":"2019","journal-title":"J Virol"},{"key":"B199","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1084\/jem.181.1.79","article-title":"Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment","volume":"181","author":"Lehner","year":"1995","journal-title":"J Exp Med"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1603106113","article-title":"Molecular basis for universal HLA-A*0201-restricted CD8+ T-cell immunity against influenza viruses","volume":"113","author":"Valkenburg","year":"2016","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B201","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/20477724.2016.1275465","article-title":"Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins","volume":"111","author":"Di Mario","year":"2017","journal-title":"Pathog Glob Health"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(85)90211-9","article-title":"Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface","volume":"40","author":"Lamb","year":"1985","journal-title":"Cell"},{"key":"B203","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12929-019-0572-3","article-title":"M2e-based universal influenza vaccines: a historical overview and new approaches to development","volume":"26","author":"Mezhenskaya","year":"2019","journal-title":"J BioMed Sci"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1038\/13484","article-title":"A universal influenza A vaccine based on the extracellular domain of the M2 protein","volume":"5","author":"Neirynck","year":"1999","journal-title":"Nat Med"},{"key":"B205","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1586\/erv.09.6","article-title":"Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments","volume":"8","author":"Schotsaert","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.64.3.1375-1377.1990","article-title":"Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice","volume":"64","author":"Treanor","year":"1990","journal-title":"J Virol"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059081","article-title":"M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A","volume":"8","author":"Ibanez","year":"2013","journal-title":"PloS One"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.33","article-title":"Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection","volume":"22","author":"Kim","year":"2014","journal-title":"Mol Ther"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902147","article-title":"Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection","volume":"186","author":"El Bakkouri","year":"2011","journal-title":"J Immunol"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.04.073","article-title":"Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e","volume":"33","author":"Tsybalova","year":"2015","journal-title":"Vaccine"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.05.041","article-title":"Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults","volume":"29","author":"Turley","year":"2011","journal-title":"Vaccine"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1038\/srep35033","article-title":"PB1 as a potential target for increasing the breadth of T-cell mediated immunity to Influenza A","volume":"6","author":"Uddback","year":"2016","journal-title":"Sci Rep"},{"key":"B213","doi-asserted-by":"publisher","first-page":"15020","DOI":"10.1038\/s41598-018-33375-1","article-title":"Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8(+) T Cell Responses","volume":"8","author":"Halbroth","year":"2018","journal-title":"Sci Rep"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2005.08.025","article-title":"Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene","volume":"13","author":"Rowe","year":"2006","journal-title":"Mol Ther"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0320-6","article-title":"Human CD8(+) T cell cross-reactivity across influenza A, B and C viruses","volume":"20","author":"Koutsakos","year":"2019","journal-title":"Nat Immunol"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.3390\/v2102290","article-title":"Tropism-modification strategies for targeted gene delivery using adenoviral vectors","volume":"2","author":"Coughlan","year":"2010","journal-title":"Viruses"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018314","article-title":"Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin","volume":"6","author":"Weaver","year":"2011","journal-title":"PloS One"},{"key":"B218","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/mt.2012.248","article-title":"Hexon-modified recombinant E1-deleted adenovirus vectors as dual specificity vaccine carriers for influenza virus","volume":"21","author":"Zhou","year":"2013","journal-title":"Mol Ther"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68076-8","article-title":"Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice","volume":"367","author":"Hoelscher","year":"2006","journal-title":"Lancet (London England)"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186244","article-title":"Adenovirus vector-based multi-epitope vaccine provides partial protection against H5, H7, and H9 avian influenza viruses","volume":"12","author":"Hassan","year":"2017","journal-title":"PloS One"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204776","article-title":"Structure and applications of novel influenza HA tri-stalk protein for evaluation of HA stem-specific immunity","volume":"13","author":"Lu","year":"2018","journal-title":"PloS One"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900379","article-title":"A Computationally Optimized Broadly Reactive Antigen Subtype-Specific Influenza Vaccine Strategy Elicits Unique Potent Broadly Neutralizing Antibodies against Hemagglutinin","volume":"204","author":"Sautto","year":"2020","journal-title":"J Immunol"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092822","article-title":"Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses","volume":"9","author":"Lin","year":"2014","journal-title":"PloS One"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.3390\/v9080234","article-title":"An Adenovirus-Vectored Influenza Vaccine Induces Durable Cross-Protective Hemagglutinin Stalk Antibody Responses in Mice","volume":"9","author":"Kim","year":"2017","journal-title":"Viruses"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00823-14","article-title":"Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice","volume":"88","author":"Kim","year":"2014","journal-title":"J Virol"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062496","article-title":"Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness","volume":"8","author":"Vemula","year":"2013","journal-title":"PloS One"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.12.003","article-title":"Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice","volume":"16","author":"Bliss","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301290","article-title":"Adenovirus-based vaccine against Listeria monocytogenes: extending the concept of invariant chain linkage","volume":"191","author":"Jensen","year":"2013","journal-title":"J Immunol"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001877","article-title":"Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain","volume":"186","author":"Mikkelsen","year":"2011","journal-title":"J Immunol"},{"key":"B230","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1128\/CVI.00552-12","article-title":"An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models","volume":"20","author":"Scallan","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.01.023","article-title":"Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-gamma T cell responses in humans","volume":"31","author":"Peters","year":"2013","journal-title":"Vaccine"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033428","article-title":"Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine","volume":"7","author":"Pandey","year":"2012","journal-title":"PloS One"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.08.066","article-title":"Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1","volume":"34","author":"Cheng","year":"2016","journal-title":"Vaccine"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00256-06","article-title":"Characterization of a permissive epitope insertion site in adenovirus hexon","volume":"80","author":"McConnell","year":"2006","journal-title":"J Virol"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2017.10.005","article-title":"Retargeted and detargeted adenovirus for gene delivery to the muscle","volume":"514","author":"Nguyen","year":"2018","journal-title":"Virology"},{"key":"B236","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1038\/s41598-017-02019-1","article-title":"Both haemagglutinin-specific antibody and T cell responses induced by a chimpanzee adenoviral vaccine confer protection against influenza H7N9 viral challenge","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PloS One"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aau2710","article-title":"Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine","volume":"4","author":"Matsuda","year":"2019","journal-title":"Sci Immunol"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.1.200","article-title":"The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity","volume":"176","author":"Yang","year":"2006","journal-title":"J Immunol"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830251239","article-title":"Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector","volume":"25","author":"Juillard","year":"1995","journal-title":"Eur J Immunol"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8040574","article-title":"Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines","volume":"8","author":"Sayedahmed","year":"2020","journal-title":"Vaccines"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","author":"Zhu","year":"2020","journal-title":"Lancet (London England)"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.09.031","article-title":"Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy","volume":"36","author":"Sayedahmed","year":"2018","journal-title":"Vaccine"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003548","article-title":"Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice","volume":"3","author":"Croyle","year":"2008","journal-title":"PloS One"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e32833d2d2b","article-title":"Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag\/pol\/nef subtype B HIV vaccine","volume":"5","author":"Gray","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet (London England)"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328342115c","article-title":"Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study","volume":"25","author":"Curlin","year":"2011","journal-title":"AIDS"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis285","article-title":"Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials","volume":"205","author":"Stephenson","year":"2012","journal-title":"J Infect Dis"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01878-08","article-title":"Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer","volume":"83","author":"Parker","year":"2009","journal-title":"J Virol"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2014.007","article-title":"Challenges in manufacturing adenoviral vectors for global vaccine product deployment","volume":"25","author":"Vellinga","year":"2014","journal-title":"Hum Gene Ther"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis232","article-title":"A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection","volume":"205","author":"Giles","year":"2012","journal-title":"J Infect Dis"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7203","article-title":"Graph-based optimization of epitope coverage for vaccine antigen design","volume":"37","author":"Theiler","year":"2018","journal-title":"Stat Med"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01677","article-title":"Protective Antibodies Against Influenza Proteins","volume":"10","author":"Padilla-Quirarte","year":"2019","journal-title":"Front Immunol"},{"key":"B254","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1038\/s41467-018-06228-8","article-title":"A naturally protective epitope of limited variability as an influenza vaccine target","volume":"9","author":"Thompson","year":"2018","journal-title":"Nat Commun"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00700-11","article-title":"A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin","volume":"85","author":"Krause","year":"2011","journal-title":"J Virol"},{"key":"B256","doi-asserted-by":"publisher","first-page":"4460","DOI":"10.1016\/j.celrep.2019.11.084","article-title":"Identification of Antibodies Targeting the H3N2 Hemagglutinin Receptor Binding Site following Vaccination of Humans","volume":"29","author":"Zost","year":"2019","journal-title":"Cell Rep"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000350","article-title":"Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses","volume":"5","author":"Yoshida","year":"2009","journal-title":"PloS Pathog"},{"key":"B258","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.chom.2019.04.003","article-title":"Influenza Antigen Engineering Focuses Immune Responses to a Subdominant but Broadly Protective Viral Epitope","volume":"25","author":"Bajic","year":"2019","journal-title":"Cell Host Microbe"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1038\/nature11414","article-title":"Cross-neutralization of influenza A viruses mediated by a single antibody loop","volume":"489","author":"Ekiert","year":"2012","journal-title":"Nature"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03562-13","article-title":"A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head","volume":"88","author":"Benjamin","year":"2014","journal-title":"J Virol"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05397-11","article-title":"Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5","volume":"85","author":"Ohshima","year":"2011","journal-title":"J Virol"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1715471115","article-title":"Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody","volume":"115","author":"Raymond","year":"2018","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1126\/science.aag1322","article-title":"Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting","volume":"354","author":"Gostic","year":"2016","journal-title":"Sci (New York NY"},{"key":"B264","doi-asserted-by":"publisher","first-page":"4566","DOI":"10.1038\/s41467-020-18465-x","article-title":"Middle-aged individuals may be in a perpetual state of H3N2 influenza virus susceptibility","volume":"11","author":"Gouma","year":"2020","journal-title":"Nat Commun"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.03243-19","article-title":"Influenza Virus Infection Induces a Narrow Antibody Response in Children but a Broad Recall Response in Adults","volume":"11","author":"Meade","year":"2020","journal-title":"mBio"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.607333\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T14:33:17Z","timestamp":1697725997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.607333\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":265,"alternative-id":["10.3389\/fimmu.2020.607333"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.607333","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]},"article-number":"607333"}}